



## ASX ANNOUNCEMENT

### Quarterly Cashflow report

**Melbourne, Australia; 27 October 2011:** Starpharma (ASX: SPL; OCTQX: SPHRY) today released its Appendix 4C - Quarterly Cashflow report for the period ended 30 September 2011.

The cash balance at 30 September 2011 was \$17m. Total operating and investing cash outflow for the quarter was \$2.1m. Major activities during the quarter included:

- Positive End of Phase 2 meeting with the FDA, paving the way for commencement of the Phase 3 program for VivaGel<sup>®</sup> for the treatment of Bacterial Vaginosis (BV);
- Commencement of the Phase 2 study of VivaGel<sup>®</sup> for prevention of BV;
- Initial results of Starpharma's internal agrochemical program demonstrating Starpharma's Priostar<sup>®</sup> dendrimers improve the performance of major agrochemical agents including glyphosate (the active ingredient in Roundup<sup>®</sup>); and
- further studies of Starpharma's dendrimer-Docetaxel formulation in the Company's drug delivery program.

Starpharma also signed and commenced several new drug delivery and agrochemical partnered programs during the quarter. The company now has a broad range of commercial partnerships in these two areas, including with Lilly, GSK, Elanco, and a number of undisclosed industry-leading partners.

#### ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KGaA.

The Company's lead pharmaceutical development product is VivaGel<sup>®</sup> (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV, genital herpes and bacterial vaginosis. Starpharma has a licence agreement with Ansell Limited to develop a VivaGel<sup>®</sup>-coated condom, and a licence agreement with Okamoto Industries Inc in relation to the VivaGel<sup>®</sup>-coated condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

Starpharma also has agreements in place with Lilly, Elanco, Stiefel Laboratories (a GSK Company), and Siemens Healthcare as well as many research collaborations with some of the world's leading organisations in the fields of pharmaceuticals, drug delivery, cosmetics and agrochemicals.

A dendrimer is a type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

**American Depository Receipts (ADRs):** Starpharma's ADRs trade under the code **SPHRY** (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Securities Exchange (ASX). Starpharma's ADRs are listed on International OTCQX, a premium market tier in the U.S. for international exchange-listed companies.

FOR FURTHER INFORMATION		
<b>Media:</b> Buchan Consulting Haley Price Mob: +61 423 139163 <a href="mailto:hprice@buchanwe.com.au">hprice@buchanwe.com.au</a>	<b>Starpharma:</b> Dr Jackie Fairley Chief Executive Officer +61 3 8532 2704	Ben Rogers Company Secretary +61 3 8532 2702 <a href="mailto:ben.rogers@starpharma.com">ben.rogers@starpharma.com</a>

### Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Name of entity

**Starpharma Holdings Limited**

ABN

**20 078 532 180**

Quarter ended ("current quarter")

**30 September 2011****Consolidated statement of cash flows**

		Current Quarter \$A'000	Year to Date \$A'000
<b>Cash flows related to operating activities</b>			
1.1	Receipts from customers	511	511
1.2	Payments for		
	(a) staff costs	(1,176)	(1,176)
	(b) advertising and marketing	-	-
	(c) research and development	(1,704)	(1,704)
	(d) leased assets	(13)	(13)
	(e) other working capital	-	-
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	252	252
1.5	Interest and other costs of finance paid	(2)	(2)
1.6	Income taxes paid	-	-
1.7	Other	-	-
	<b>Net operating cash flows</b>	<b>(2,132)</b>	<b>(2,132)</b>
<b>Cash flows related to investing activities</b>			
1.9	Payment for acquisition of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	(4)	(4)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other	-	-
	<b>Net investing cash flows</b>	<b>(4)</b>	<b>(4)</b>
1.14	<b>Total operating and investing cash flows</b>	<b>(2,136)</b>	<b>(2,136)</b>
<b>Cash flows related to financing activities</b>			
1.15	Proceeds from issues of shares	102	102
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other	-	-
	<b>Net financing cash flows</b>	<b>102</b>	<b>102</b>
	<b>Net increase (decrease) in cash held</b>	<b>(2,034)</b>	<b>(2,034)</b>
1.21	Cash at beginning of quarter/year to date	18,918	18,918
1.22	Exchange rate adjustments	92	92
1.23	<b>Cash at end of quarter</b>	<b>16,976</b>	<b>16,976</b>

**Payments to directors of the entity and associates of the directors**  
**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	(318)
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	

Item 1.24 consists of the following:

- (a) Remuneration paid to the Chief Executive Officer.
- (b) Director's fees paid to non-executive directors.

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

--	--

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Nil	
-----	--

**Financing facilities available**

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

--	--

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities - Lease facility for laboratory equipment	297	52
3.2	Credit standby arrangements - Credit card facility	130	16

Item 3.1 A \$97,000 lease facility guaranteed by term deposit and a \$200,000 master asset finance facility with National Australia Bank for laboratory equipment.

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	2,115	2,098
4.2	Deposits at call	14,861	16,820
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
<b>Total: cash at end of quarter (item 1.23)</b>		<b>16,976</b>	<b>18,918</b>

## Acquisitions and disposals of business entities

- 5.1 Name of entity
- 5.2 Place of incorporation or registration
- 5.3 Consideration for acquisition or disposal
- 5.4 Total net assets
- 5.5 Nature of business

Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
-	-
-	-
-	-
-	-
-	-

## Compliance statement

1. This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Law (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
  
2. This statement does give a true and fair view of the matters disclosed.



27 October 2011

B P Rogers  
Company Secretary